Federico Caligaris-Cappio

Federico Caligaris-Cappio

Auto-generated profile, based on publicly available information

Federico Caligaris-Cappio

From the Department of Oncological Sciences, University of Torino, Institute for Cancer Research and Treatment (IRCC), Candiolo (TO) and Division of Clinical Immunology and Hematology, Ospedale Mauriziano Umberto I, Torino, Italy

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1999 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FCFederico Caligaris-Cappio
Federico Caligaris-Cappio
THTerry J. Hamblin
Terry J. Hamblin
PURPOSE: To review the recent major advances in the molecular and cell biology of B-cell chronic lymphocytic leukemia (B-CLL).METHODS: We analyzed the nature of malignant B-CLL B cells and their interactions with the microenvironment.RESULTS: B-CLL is a malignancy of a mantle zone-based subpopulation of anergic, self-reactive, activated CD5+B cells devoted to the production of polyreactive natural autoantibodies. It is the quintessential example of a human malignancy that primarily involves defects in the induction of programmed cell death. An abnormal karyotype is observed in about 50% of patients with B-CLL. Patients with 13q14 abnormalities show heavy somatic mutation and have a benign disease. Trisomy 12 is associated with unmutated VH genes, atypical cellular morphology, and progressive disease. Extended cell survival is further shielded by a kinetic refractoriness likely promoted by abnormalities of the B-cell antigen receptor complex and favored by some cytokines that highlight a reciprocal dialog between malignant B and T cells. Because the tumor cells act as the major accessory cells, the accumulating malignant B-cell population per se is a hurdle to the production of normal antibodies and leads to a progressive and severe hypogammaglobulinemia. Conceivably, in the presence of certain immunoglobulin genes and when the T-cell control becomes deficient, activated malignant B cells may become able to present self-antigens and drive residual normal B cells to produce polyclonal autoantibodies restricted to self-antigens expressed only by blood cells and cause autoimmune cytopenias.CONCLUSION: The distinctiveness of B-CLL B cells explains why B-CLL is different from other B-cell tumors and accounts for the development of immune deficiency and autoimmunity.

1 May 2001 in Blood
Verified
Journal Article
Open access
LGLuisa Granziero
Luisa Granziero
PGPaolo Prospero Ghia
Paolo Prospero Ghia
PCPaola Circosta
Paola Circosta
DGDaniela Gottardi
Daniela Gottardi
GSGiuliana Strola
Giuliana Strola
FCFederico Caligaris-Cappio
Federico Caligaris-Cappio
In B-cell chronic lymphocytic leukemia (B-CLL), defective apoptosis causes the accumulation of mature CD5+ B cells in lymphoid organs, bone marrow (BM), and peripheral blood (PB). These cells are the progeny of a proliferating pool that feeds the accumulating compartment. The authors sought to determine which molecular mechanisms govern the proliferating pool, how they relate to apoptosis, and what the role is of the microenvironment. To begin to resolve these problems, the expression and modulation of the family of inhibitor of apoptosis proteins (IAPs) were investigated, with consideration given to the possibility that physiological stimuli, such as CD40 ligand (CD40L), available to B cells in the microenvironment, might modulate IAP expression. The in vitro data on mononuclear cells from PB or BM of 30 patients demonstrate that B-CLL cells on CD40 stimulation express Survivin and that Survivin is the only IAP whose expression is induced by CD40L. Through immunohistochemistry, in vivo Survivin expression in lymph node (LN) and BM biopsies was evaluated. In reactive LN, Survivin was detected only in highly proliferating germinal center cells. In LN from patients with B-CLL, Survivin was detected only in pseudofollicles. Pseudofollicle Survivin+ cells were actively proliferating and, in contrast to Survivin+ B cells found in normal GC, were Bcl-2+. In B-CLL BM biopsies, CD5+, Survivin+ cells were observed in clusters interspersed with T cells. These findings establish that Survivin controls the B-CLL proliferative pool interfacing apoptosis and that its expression may be modulated by microenvironmental stimuli.

1 May 2002 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
PGPaolo Prospero Ghia
Paolo Prospero Ghia
GSGiuliana Strola
Giuliana Strola
LGLuisa Granziero
Luisa Granziero
MGMassimo Geuna
Massimo Geuna
GGGiuseppe Guida
Giuseppe Guida
FCFederico Caligaris-Cappio
Federico Caligaris-Cappio

15 February 2003 in Blood
Verified
Journal Article
Open access
PDF file
PGPaolo Prospero Ghia
Paolo Prospero Ghia
GGGiuseppe Guida
Giuseppe Guida
SSStefania Stella
Stefania Stella
DGDaniela Gottardi
Daniela Gottardi
MGMassimo Geuna
Massimo Geuna
FCFederico Caligaris-Cappio
Federico Caligaris-Cappio
Chronic lymphocytic leukemia (CLL) has a variable clinical course. CD38 expression and IgVH gene mutational status are independent predictors of prognosis, but their relationships and the CD38 cutoff level are unknown. Using cytofluorography, we analyzed CD38 in 148 patients, in 108 of whom we were able to evaluate IgVH mutations, make correlations with disease history, and assess cumulative survival. Three different patient groups were identified by the CD38 expression pattern: a group homogeneously CD38−, a group homogeneously CD38+, and a group characterized by a bimodal profile, because of the concomitant presence of variable proportions of 2 distinct populations, one CD38+ and one CD38−. In CD38 bimodal expression patients the CD38+ subset was significantly more represented in the bone marrow than in the peripheral blood. For IgVH mutations, 11.4% of CD38−, 84.6% of CD38+, and 68.0% of CD38 bimodal expression patients had no mutation. CD38 expression, IgVH mutational status, and traditional prognostic factors were concordant. The progression rate was 12.9% for CD38−, 75.0% for CD38+, and 63.3% for CD38 bimodal expression patients. Only 25.8% of the CD38−patients but 63.3% of the bimodal and 75.0% of CD38+patients were treated. The presence of a CD38+ population, albeit small, correlated with the development of autoimmune manifestations. The CD38− group has not yet reached the median survival, which is 183 months in the CD38+ group and 156 months in the CD38 bimodal expression group, regardless of the size of the CD38+ population. The presence of a distinct CD38+ population within the leukemic clone, rather than a numerical cutoff definition, correlates with IgVH gene mutational status and, irrespective of its size, identifies CLL patients who will have progressive disease.

1 March 2003 in Blood
Verified
Journal Article
Open access
PDF file
LGLuisa Granziero
Luisa Granziero
PCPaola Circosta
Paola Circosta
CSCristina Scielzo
Cristina Scielzo
EFElisa Frisaldi
Elisa Frisaldi
SSStefania Stella
Stefania Stella
FCFederico Caligaris-Cappio
Federico Caligaris-Cappio
Growth and survival of chronic B-cell tumors are favored by the malignant cell's capacity to respond to selected microenvironmental stimuli provided by nontumoral bystander cells. To investigate which mechanisms operate in these crosstalks and whether they are malignancy-related or reproduce the mechanisms used by normal B cells we have studied the expression and functional role of semaphorin CD100 (now called Sema4D) in chronic lymphocytic leukemia (CLL) cells and normal CD5+ B cells. We demonstrate here that (1) leukemic and normal CD5+ B lymphocytes uniformly express CD100; (2) the CD100 high-affinity receptor Plexin-B1 is expressed by bone marrow stromal cells, follicular dendritic cells, and activated T lymphocytes, and is thus available to CD100+ lymphocytes in different specific microenvironments; and (3) upon interaction between CD100 and Plexin-B1 both CLL and normal CD5+ B cells increase their proliferative activity and extend their life span. These findings establish that Plexin-B1 is an easily accessible receptor for CD100 within the immune system. The encounter of CD100+ leukemic cells with Plexin-B1 may promote the proliferation and survival of malignant cells. The crosstalk operated by the CD100/Plexin-B1 interaction is not malignancy related but reproduces a mechanism used by normal CD5+ B cells.

27 July 2010 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
CSCristina Scielzo
Cristina Scielzo
EHElisa Ten Hacken
Elisa Ten Hacken
MBMaria T. S. Bertilaccio
Maria T. S. Bertilaccio
MMMarta Muzio
Marta Muzio
CCCarlo Calissano
Carlo Calissano
FCFederico Caligaris-Cappio
Federico Caligaris-Cappio
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation in primary and secondary lymphoid tissues of CD5+ B cells that have the same B cell receptor (BCR) rearrangement. Genetic alterations and different stimuli originating from the microenvironment cooperate in the selection and expansion of the malignant clone. Molecular and functional analyses suggest that stimulation through the BCR affects the destiny of leukemic cells in terms of life or death. Microenvironmental signals are crucial for this process, inducing proliferation and leading to the survival and accumulation of leukemic cells within lymphoid organs. Nevertheless, a number of major biological issues still remain to be solved, including the relationships between cell proliferation and cell accumulation within lymphoid organs as well as the mechanisms that regulate CLL cell migration and recirculation between peripheral blood and lymphoid tissues. We focused on the role played by the cytoskeleton, given its relevance in controlling cellular shape, mobility, and homing. We hypothesize that hematopoietic cell-specific Lyn substrate 1 (HS1), a putative prognostic marker in CLL that interacts with distinct cytoskeleton adapters in leukemic B-lymphocytes, could regulate the CLL cell cytoskeleton.